This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Direct purchaser defends US antitrust case over Colcrys

( February 1, 2023, 22:31 GMT | Official Statement) -- MLex Summary: Value Drug Co. opposed a motion for judgment against claims that Watson Laboratories, Teva Pharmaceutical, Amneal Pharmaceuticals, and Takeda conspired to allocate the generic Colcrys market and delay entry by later-filing generics. “Plaintiff has proffered extensive direct (and strong circumstantial) evidence of concerted action, all of it ‘sufficiently unambiguous.’ The conspirators’ written agreements and admissions about the purpose and effect of their mutual promises constitute direct evidence of the conspiracy,” it argued.See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections